HPV Vaccination after Primary Treatment of HPV-Related Disease across Different Organ Sites: A Multidisciplinary Comprehensive Review and Meta-Analysis

Vaccines

卷:10

Ilaria Clementi¹  Ilaria Cuccu²  Nadia Recine²  Sara Sorrenti²  Ludovico Muzii²  Giuseppe Caruso²  Federica Tanzi²  Violante Di Donato²  Giorgio Bogani²  Giorgia Perniola²  Innocenza Palaia²  Pasquale Mancino²  Alessandra Pierangeli³  Guido Antonelli³  Valentino Valentini⁴  Marco de Vincentiis⁴  Gaspare Palaia⁴  Antonella Polimeni⁴  Umberto Romeo⁴  Andrea Cassoni⁴  Claudio Maria Mastroianni⁵  Eugenio Nelson Cavallari⁵  Gabriella d’Ettorre⁵  Carlo Della Rocca⁶  Angelina Pernazza⁶  Massimo Ralli⁷  Andrea Mingoli⁸ 

[1] Department of Emergency, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy;

[2] Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy;

[3] Department of Molecular Medicine, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy;

[4] Department of Oral and Maxillofacial Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy;

[5] Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy;

[6] Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy;

[7] Department of Sense Organs, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy;

[8] Department of Surgery “Pietro Valdoni”, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy;

关键词: human papillomavirus;    HPV;    vaccination;    cervical cancer;    vulvar cancer;    anogenital warts;   

DOI  :  10.3390/vaccines10020239

来源: DOAJ

【 摘 要 】

Objective: To assess evidence on the efficacy of adjuvant human papillomavirus (HPV) vaccination in patients treated for HPV-related disease across different susceptible organ sites. Methods: A systematic review was conducted to identify studies addressing the efficacy of adjuvant HPV vaccination on reducing the risk of recurrence of HPV-related preinvasive diseases. Results were reported as mean differences or pooled odds ratios (OR) with 95% confidence intervals (95% CI). Results: Sixteen studies were identified for the final analysis. Overall, 21,472 patients with cervical dysplasia were included: 4132 (19.2%) received the peri-operative HPV vaccine, while 17,340 (80.8%) underwent surgical treatment alone. The recurrences of CIN 1+ (OR 0.45, 95% CI 0.27 to 0.73; p = 0.001), CIN 2+ (OR 0.33, 95% CI 0.20 to 0.52; p < 0.0001), and CIN 3 (OR 0.28, 95% CI 0.13 to 0.59; p = 0.0009) were lower in the vaccinated than in unvaccinated group. Similarly, adjuvant vaccination reduced the risk of developing anal intraepithelial neoplasia (p = 0.005) and recurrent respiratory papillomatosis (p = 0.004). No differences in anogenital warts and vulvar intraepithelial neoplasia recurrence rate were observed comparing vaccinated and unvaccinated individuals. Conclusions: Adjuvant HPV vaccination is associated with a reduced risk of CIN recurrence, although there are limited data regarding its role in other HPV-related diseases. Further research is warranted to shed more light on the role of HPV vaccination as adjuvant therapy after primary treatment.

【 授权许可】

Unknown